Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated NSCLC By Ogkologos - August 20, 2025 393 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KRYSTAL-12 study Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR More than 65,000 people are left waiting to find out if... May 8, 2022 Lo que deben saber las personas con cáncer de mama y... January 4, 2024 Tipifarnib Demonstrates Encouraging Efficacy in Patients with Recurrent and/or Metastatic HNSCC... April 21, 2021 Adjuvant Alectinib Significantly Improves Disease-Free Survival in Patients with Resected ALK-positive... April 18, 2024 Load more HOT NEWS 120 years of discovery: 10 ways we’ve changed the story for... Newly Discovered ‘Don’t Eat Me’ Signal May be a Target for... Long-Term Follow-Up Data Support Longer RFS with Adjuvant Nivolumab Than with... Study Shows Thymic Health is Linked to Cancer Patients’ Response to...
